Table 5. Stratification analysis for associations between combined risk genotypes of mTOR variants and prostate cancer risk.

Variables	Combined effect of risk genotypes (cases/controls)		Crude OR(95%CI)	P	Adjusted OR(95%CI)a	P a	P b	Interaction
	0–1 at-risk genotype	2-6 at-risk genotype						P c
Age, yr
≤69 (median)	236/301	274/267	1.31 (1.03–1.66)	0.028	1.29 (1.02–1.65)	0.036	0.473	0.872
>69 (median)	230/242	264/241	1.15 (0.90–1.48)	0.268	1.15 (0.90–1.48)	0.271
BMI, kg/m2
≤24	348/336	406/301	1.30 (1.05–1.61)	0.014	1.31 (1.06–1.61)	0.013	0.431	0.431
>24	118/207	132/207	1.12 (0.82–1.53)	0.484	1.11 (0.81–1.52)	0.527
Smoking status
Never	185/201	217/207	1.14 (0.86–1.50)	0.356	1.15 (0.87–1.52)	0.322	0.470	0.470
Ever	281/342	321/301	1.30 (1.04–1.62)	0.022	1.29 (1.03–1.61)	0.027
Gleason score
≤7(3+4)	133/543	179/508	1.44 (1.12–1.86)	0.005	1.46 (1.13–1.89)	0.004	0.258
≥7(4+3)	284/543	317/508	1.19 (0.98–1.46)	0.085	1.19 (0.98–1.46)	0.084
Stage of disease
I+II	208/543	228/508	1.17 (0.94–1.47)	0.165	1.18 (0.95–1.48)	0.140	0.400
III+ IV	218/543	273/508	1.34 (1.08–1.66)	0.008	1.34 (1.08–1.66)	0.008

^aObtained in logistic dominant models with adjustment for age, smoking status and BMI.

^b P for homogeneity test using the χ2-based Q test.

^cTest for multiplicative interaction obtained from logistic regression models with adjustment for age, smoking status and BMI.

CI, confidence interval; BMI, body mass index.

The results were in bold, if P<0.05.